Exploratory PET Study to Evaluate the Effects of ABT-614 on [11C]-(+)-PHNO Binding Potential to D3 Receptors in the Brain.
Latest Information Update: 14 Jan 2020
At a glance
- Drugs ABT-614 (Primary)
- Indications Substance-related disorders
- Focus Pharmacokinetics
- Sponsors Abbott Laboratories
- 04 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Apr 2009 Actual number of patients added (11) as reported by ClinicalTrials.gov.
- 08 Apr 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.